Clene’s (NASDAQ: CLNN) lead drug candidate CNM-Au8 was the subject of two Phase 2a clinical trials, REPAIR-PD and REPAIR-MS, which evaluated the effects of CNM-Au8 on brain energy metabolite levels in participants with diagnoses of idiopathic Parkinson’s Disease (“PD”) and relapsing Multiple Sclerosis (“MS”), respectively. The REPAIR-PD and REPAIR-MS Phase 2 trials expanded the documented evidence of CNM-Au8’s positive effects demonstrated by in vitro studies, which have shown that the surfaces of the drug candidate’s nanocrystals catalyze the rapid oxidation of NADH to NAD+, increasing the intracellular availability of both NAD+ and ATP. NAD+ supports the synthesis of ATP, the universal energy-containing molecule that powers most cellular functions, including brain function. The results of the REPAIR-PD and REPAIR-MS trials, which showed that treatment with CNM-Au8 resulted in a statistically significant (p < 0.05) 10.4% increase in the brain NAD+/NADH ratio, were described in a peer-review article published in the Journal of Nanobiotechnology. “We believe the 10.4% increase in brain NAD+/NADH ratio to be clinically significant. Other groups have shown significant deficits in brain energy metabolites associated with neurodegenerative disease,” a recent article quotes Dr. Benjamin Greenberg, Head of Medical at Clene, as saying. “Elevation of brain NAD+/NADH levels to many times the rate of loss observed in healthy aging is a significant and very promising effect.”
To view the full article, visit https://ibn.fm/mrLCT
About Clene Inc.
Clene (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease and multiple sclerosis. CNM-Au8(R) is an investigational first-in-class therapy that improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8(R) is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.Clene.com.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN
Corporate Communications
IBN (InvestorBrandNetwork)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
[email protected]